Edwards Weathers TAVI Storm
Edwards Lifesciences’ position as leader of the transcatheter aortic valve implantation market is looking secure. Furthermore, the segment could end up being even bigger than anticipated.
You may also be interested in...
Edwards Lifesciences will bring its next-generation transcatheter aortic valve implant (TAVI) system, Sapien XT to the U.S. just in time to face the growing threat of competition from Medtronic’s CoreValve, which earned an expanded FDA indication for patients at high risk for surgery.
Post-litigation settlement, Edwards Lifesciences is again facing competition from arch TAVI rival Medtronic, but it’s third-generation Sapien 3 device could save the day. Edwards presented late-breaking data from the SAPIEN 3 trial at the EuroPCR meeting, held in Paris in May.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.